Table 1 Demographic and clinical characteristics
EINSTEIN-DVT[8] | EINSTEIN-PE[9] | EINSTEIN pooled | ||||
|---|---|---|---|---|---|---|
Rivaroxaban | Enoxaparin/VKA | Rivaroxaban | Enoxaparin/VKA | Rivaroxaban | Enoxaparin/VKA | |
(N = 1731) | (N = 1718) | (N = 2419) | (N = 2413) | (N = 4151) | (N = 4131) | |
Male sex–n (%) | 993 (57.4) | 967 (56.3) | 1309 (54.1) | 1247 (51.7) | 2302 (55.5) | 2214 (53.6) |
Mean age–years ± SD | 55.8 ± 16.4 | 56.4 ± 16.3 | 57.9 ± 7.3 | 57.5 ± 7.2 | 57.0 ± 17.0 | 57.0 ± 16.8 |
Risk factor associated with VTE–n (%) | ||||||
Recent surgery or trauma | 338 (19.5) | 335 (19.5) | 415 (17.2) | 398 (16.5) | 753 (18.1) | 733 (17.7) |
Previous VTE | 336 (19.4) | 330 (19.2) | 455 (18.8) | 489 (20.3) | 791 (19.1) | 819 (19.8) |
Active cancer | 118 (6.8) | 89 (5.2) | 114 (4.7) | 109 (4.5) | 232 (5.6) | 198 (4.8) |
Estrogen therapy | 140 (8.1) | 115 (6.7) | 207 (8.6) | 223 (9.2) | 347 (8.4) | 338 (8.2) |
Immobilization | 265 (15.3) | 260 (15.1) | 384 (15.9) | 380 (15.7) | 649 (15.6) | 640 (15.5) |
Known thrombophilic condition | 107 (6.2) | 116 (6.8) | 138 (5.7) | 121 (5.0) | 245 (5.9) | 237 (5.7) |
Unprovoked VTE | 1055 (60.9) | 1083 (63.0) | 1566 (64.7) | 1551 (64.3) | 2621 (63.1) | 2634 (63.8) |
Duration of study treatment–days (mean [SD])* | 193.6 (89.3) | 187.5 (92.5) | 216.3 (98.7) | 214.3 (98.9) | 207.6 ± 95.9 | 203.8 ± 97.4 |